Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

CTT: Cholesterol Treatment Trialists' Collaboration

Established in 1994

Data from 175,000 statin users

The Cholesterol Treatment Trialists’ (CTT) Collaboration conducts meta-analyses of cholesterol intervention trials. It was originally established in 1994 with the aim of bringing together data for each participant in all of the large-scale, long-term randomised controlled trials of statin therapy in order to be able to assess - more reliably than was possible with any of the individual trials - the effects of such therapy in different types of people. The Collaboration currently holds data on heart attacks, strokes, revascularisation procedures, cause-specific mortality and cancers from about 30 such statin trials equating to approximately 175,000 individuals. The CTT Collaboration’s work is coordinated jointly by Clinical Trial Service Unit & Epidemiological Studies Unit in Oxford and the National Health and Medical Research Council Clinical Trials Centre in Sydney.

The CTT Collaboration has shown that lowering LDL cholesterol using statin therapy reduces the risk of major vascular events (heart attacks, stroke or coronary revascularisation procedures) by about one fifth for each 1 mmol/L reduction in LDL cholesterol achieved. These benefits are achieved in a wide range of people at risk of cardiovascular disease, irrespective of pre-existing cardiovascular disease or diabetes, and regardless of age, sex and other factors.

The results of the CTT’s work also indicate that statin therapy does not increase the risk of non-vascular causes of death or of cancer. The Collaboration is currently collecting new data from participating trials to examine the effects of statins on adverse events other than death and cancer.

Our team

Funding

Medical Research Council

Cancer Research UK

British Heart Foundation

Selected publications

PUBLICATIONS AND ASSOCIATED MATERIALS

Related research themes

Meta-analyses of randomised trials
Meta-analyses of randomised trials
Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease, angina, heart attack, congenital heart disease and stroke. Despite improvements in the prevention and treatment of CVD in recent decades, it remains the leading cause of death worldwide, particularly in developed countries.
Cardiovascular disease
Blood lipids are a major cause of cardiovascular disease. Higher levels of LDL cholesterol and lower levels of HDL cholesterol are associated with higher heart disease risk. While this has been known for some time, effective treatments to substantially lower LDL cholesterol have only become available in recent decades.
Cholesterol